2026 VA/DoD Menopause Guideline Brings Intimacy Into the Care Conversation

An October 6, 2026 announcement highlighted the 2026 menopause clinical practice guideline published by VA/DoD to support consistent care during perimenopause and menopause. The guidance includes a dedicated module on genitourinary syndrome of menopause and sexual-dysfunction symptoms.

A Wider Frame

Individualized care remains the baseline, with clinical assessment and personal priorities shaping treatment choices. The update’s stated purpose is to help clinicians provide consistent care during perimenopause and menopause, rather than establish one answer for every woman.

The change worth noticing is the scope of the framework. According to the official VA guideline page, intimate symptoms have a defined module alongside diagnosis and broader menopause management. This is an update to how care is organized, not an announcement that previous treatments should be abandoned. Comfort and sexual wellbeing have a visible place within that structure.

Inside the Guidance

The official VA materials describe several features that matter for understanding the update. They concern the organization of care and the resources supporting clinical conversations:

• Four clinical algorithms and 43 evidence-based recommendations. The guideline brings its recommendations into a structured framework for clinicians. These figures describe the complete guideline, not a set devoted only to sexual wellbeing. For readers, the useful distinction is between a comprehensive menopause resource and a treatment list for a single concern. The framework addresses different parts of care within one document. Its structure gives clinicians a way to locate the relevant discussion without treating every menopause-related question as the same problem.
• Four modules covering distinct areas of care. These address menopause/perimenopause diagnosis, menopause management, perimenopause management, and treatment of genitourinary syndrome of menopause and/or sexual-dysfunction symptoms. That final module places intimate concerns beside the wider clinical work of understanding and managing the transition. The wording also matters: the module covers GSM and/or sexual dysfunction. These are categories within the guideline, not labels every woman needs to apply to herself. A woman can describe what is affecting her comfort or desire without first deciding which clinical category fits.
• A stated goal of more consistent care. The VA describes the guideline as intended to help clinicians care consistently for people experiencing perimenopause and menopause. Consistency is best understood here as a shared framework for addressing relevant concerns. It is not the same as making identical treatment choices. From an editorial perspective, the value lies in giving intimate symptoms an identifiable place in the conversation. Questions about sexual wellbeing need not be treated as separate from the rest of midlife health simply because they are personal or difficult to phrase.
• Resources for different kinds of discussion. The official VA page provides the full guideline, a clinician summary, a quick-reference guide and a patient-provider summary. These formats make the same framework available at different levels of detail. The patient-provider summary is particularly relevant to the shared conversation between a woman and her clinician. Its presence places patient-facing information alongside professional materials. A clinical guideline is more useful to a reader when its purpose and scope are understandable, rather than appearing only as a long technical document intended for someone else.
• Treatment choice framed around the individual. The announcement presents care as a shared decision involving symptoms, personal priorities, risks and benefits. For intimate concerns, that framing matters because the desired outcome should be clear before a treatment is discussed. Comfort may be the central concern. Desire or arousal may be the question someone wants addressed. The announcement’s practical message is to bring those priorities into the discussion rather than assume that one approach suits everyone. This keeps the focus on the woman’s experience instead of turning the guideline into a universal prescription.

Comfort and desire

Giving intimate symptoms a module is a concrete organizational change. Its significance is not that every woman now needs treatment. It is that the framework explicitly makes room for a clinical conversation about this part of life.

Comfort and desire are legitimate subjects for that conversation. Neither needs to be presented as a beauty concern or a demand to maintain a particular kind of sex life. The relevant question is what the woman wants understood or addressed. That is consistent with the announcement’s focus on symptoms and personal priorities.

A useful distinction is between describing an experience and assigning it a diagnosis. “Comfort is my main concern” identifies a priority. “I want to discuss a change in desire” identifies a question. Neither statement asks the reader to decide what is causing the change or which treatment belongs with it.

This broader view connects with making room for concerns beyond hot flashes. In Refemina’s editorial approach, sexual wellbeing belongs within midlife health without becoming the only measure of wellbeing. A meaningful conversation can also acknowledge confidence and intimacy without setting expectations about how often someone should want sex.

Evidence boundaries

This announcement concerns a clinical-practice guideline update, not results from a new clinical trial. The structure of the document should not be mistaken for a newly measured improvement in sexual function or comfort. The announcement also does not establish comparative benefits for every treatment and symptom.

The treatment categories should remain distinct. The research describes therapies for sexual-interest or arousal concerns separately from local therapies and moisturizers. That separation does not support assuming that every option treats every sexual concern, or assigning a particular option to a reader’s situation.

The VA also states that the guideline assists clinicians rather than replacing clinical judgment. Personal treatment decisions therefore belong in qualified care, where symptoms and treatment trade-offs can be assessed together. The practical takeaway is clear: raise the intimate concern directly and identify the outcome that matters, rather than use the announcement as a self-treatment guide.

A clearer conversation

The most useful patient-facing message is not to arrive with a chosen therapy. It is to give the clinician a clear account of the concern and the priority attached to it. That follows the announcement’s emphasis on discussing symptoms and making decisions together.

For a comfort concern, the conversation can focus on how the experience affects intimacy and what the woman hopes care will address. For a desire or arousal concern, the discussion can begin with the change she wants understood. These are examples of describing priorities, not a checklist for determining a diagnosis. The clinical assessment remains the clinician’s responsibility.

Treatment trade-offs deserve their own space in that discussion. The announcement supports reviewing risks and benefits rather than assuming that inclusion in a guideline makes an option right for everyone. A shared decision is more than hearing the name of an available treatment. It also involves understanding why it is being discussed for this particular concern.

The guideline’s patient-provider summary offers a relevant resource for that exchange. Its role is to support dialogue alongside the professional materials, while the actual decision remains individualized. Readers who want related editorial context can also read about barriers to discussing menopause during appointments.

A good conversation does not have to end with every question resolved immediately. Its value can lie in establishing what needs assessment and what outcome matters most. That is a more grounded way to use the new framework than treating the number of recommendations as a measure of how much care any one woman needs.

Care Ahead

This framework should give comfort and desire a more consistent place in menopause consultations, while keeping treatment decisions anchored in each woman’s priorities and clinical assessment.

How Refemina helps

Comfort during intimacy is a meaningful outcome, and Refemina places it within research-led coverage of sexual wellbeing and hormonal change. Where desire or sexual confidence is ignored or sensationalised, its editorial guidance helps women distinguish credible evidence from sweeping claims without reducing a personal transition to one explanation.

Explore Resources

Sources

1. VA.gov | Veterans Affairs
2. New Clinical Guideline Helps Keep Women 'Optimized for the Fight' | Defense Dept. Press List | Forth